

May 27, 2016

---

### **MPH Mittelständische Pharma Holding AG:**

#### **Preliminary IFRS results for first quarter 2016:**

**Net profit EUR 8.69 million (20 Cent per share), equity EUR 147.71 million (3.45 EUR per share)**

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the first quarter 2016.

In the first quarter 2016 the preliminary IFRS Group net profit amounted to EUR 8.69 million (previous year period: EUR 1.26 million).

MPH reports as an investment entity according to IFRS 10 since December 31, 2015. In the transition accounting as of 31<sup>st</sup> December 2015 beforehand unrealised reserves were raised to the amount of EUR 74.71 million. This was a dominant factor for the net profit of totally EUR 84.10 million in year 2015.

The listed shares (Frankfurt Stock Exchange) of our investments HAEMATO AG, M1 Beauty AG, and CR Capital Real Estate AG are valued in the MPH reporting at the XETRA closing price at the end of each quarter. In the first quarter 2016 the share price developments were dominant for the net profit of EUR 8.69 million. The equity increased from 3.25 EUR as of 31<sup>st</sup> December 2015 to 3.45 EUR as of 31<sup>st</sup> March 2016.

The successful development of the operations is reflected in good share price developments. HAEMATO achieved in the first quarter a sales growth of +50% and doubled the profit compared to the prior year period. A dividend payment of 30 Cents per share was again proposed.

M1 announced the start of dividend payments with an initial dividend proposal of 30 Cents per share.

“We see pleasant results from the effort to perform a contribution towards maintaining healthcare affordable and are looking confident towards a continuing positive profit development in year 2016”, say Patrick Brenske and Dr. Christian Pahl, Members of the Management Board of MPH.

#### **Contact:**

MPH Mittelständische Pharma Holding AG  
Juliane Warning  
Grünauer Straße 5  
D-12557 Berlin

Phone: +49 (0) 30 897 30 86 60  
Fax: +49 (0) 30 897 30 86 69

E-Mail: [ir@mph-ag.de](mailto:ir@mph-ag.de)  
Web: [www.mph-ag.de](http://www.mph-ag.de)

May 27, 2016

---

### **About MPH Mittelständische Pharma Holding AG:**

MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments. But also beyond the healthcare market MPH makes use of potentials of high growth areas.

### Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 42,813,842

Listed shares: ordinary shares

ISIN: DE000A0L1H32

WKN: AOL1H3

Stock symbol: 93M

### **Contact:**

Juliane Warning

MPH Mittelständische Pharma Holding AG

Grünauer Straße 5

D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669

E-Mail: [ir@mph-ag.de](mailto:ir@mph-ag.de) Web: [www.mph-ag.de](http://www.mph-ag.de)

### **Contact:**

MPH Mittelständische Pharma Holding AG

Juliane Warning

Grünauer Straße 5

D-12557 Berlin

Phone: +49 (0) 30 897 30 86 60

Fax: +49 (0) 30 897 30 86 69

E-Mail: [ir@mph-ag.de](mailto:ir@mph-ag.de)

Web: [www.mph-ag.de](http://www.mph-ag.de)